Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer (MYSTIC)

Autor: Frances A. Shepherd, Sarayut Lucien Geater, Gilles Robinet, Alexander Luft, Edward B. Garon, Ki Hyeong Lee, Myung-Ju Ahn, Niels Reinmuth, Jeffrey Gary Schneider, Naiyer A. Rizvi, Ronald B. Natale, Tran Van Ngoc, Nikunj Patel, Solange Peters, Byoung Chul Cho, Zsolt Papai Szekely, Sylvestre Le Moulec, F. Liu, Marina Chiara Garassino, U. Scheuring

Publikováno v: Clinical Lung Cancer. 22:301-312.e8

The phase 3 MYSTIC study of durvalumab ± tremelimumab versus chemotherapy in metastatic non-small-cell lung cancer (NSCLC) patients with tumor cell (TC) programmed cell death ligand 1 (PD-L1) expression ≥ 25% did not meet its primary endpoints. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c212f685398a1e9dafa6cd13fc526ef
https://doi.org/10.1016/j.cllc.2021.02.010

Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP)

Autor: SA Husain, Milena Encheva, Zsolt Papai-Szekely, Hervé Dutau, Lars Ek, Christophe Dooms, Ales Rozman, Levent Dalar, Martin Hackl, Stefano Gasparini, Semra Bilaceroglu, Bojan Zaric, Muhammed Munavvar, Felix J.F. Herth, Johannes M.A. Daniels, Artur Szlubowski, Lina Zuccatosta, Marija Zdraveska, Toomas Uibu, António Bugalho, Christophe von Garnier, Arve Sundset, Darijo Bokan, Michel Febvre, Mihovil Roglic, Sirje Marran, Ralf Eberhardt, Paola Marina Alessandra Gasche-Soccal, Pallav L. Shah, Marioara Simon, Grigoris Stratakos, Michael Perch, David P. Breen, Antoni Rosell

Publikováno v: Respiration, vol. 95, no. 1, pp. 44-54, 2018.
Respiration, 95(1), 44-54. S. Karger AG
Dipòsit Digital de la UB
Universidad de Barcelona
Dutau, H, Breen, D, Bugalho, A, Dalar, L, Daniels, J, Dooms, C, Eberhardt, R, Ek, L, Encheva, M, Febvre, M, Hackl, M, Marran, S, Papai-Szekely, Z, Perch, M, Roglic, M, Rosell, A, Rozman, A, Shah, P L, Simon, M, Szlubowski, A, Stratakos, G, Sundset, A, Uibu, T, von Garnier, C, Zaric, B, Zdraveska, M, Zuccatosta, L, Bokan, D, Arshad Husain, S, Bilaceroglu, S, Gasche-Soccal, P, Gasparini, S, Herth, F J F & Munavvar, M 2018, ' Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP) ', Respiration, vol. 95, no. 1, pp. 44-54 . https://doi.org/10.1159/000480152
Respiration; international review of thoracic diseases, Vol. 95, No 1 (2018) pp. 44-54

Background: Airway stenting (AS) commenced in Europe circa 1987 with the first placement of a dedicated silicone airway stent. Subsequently, over the last 3 decades, AS was spread throughout Europe, using different insertion techniques and different

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e716f8123d1210bdaf7e51a492cca66

Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC

Autor: F. Liu, Ronald B. Natale, Ki Hyeong Lee, Alexander Luft, Naiyer A. Rizvi, Zsolt Papai-Szekely, Solange Peters, Niels Reinmuth, Frances A. Shepherd, Byoung Chul Cho, Myung-Ju Ahn, Sylvestre Le Moulec, Jeffrey Gary Schneider, Marina Chiara Garassino, U. Scheuring, Sarayut Lucien Geater, Anna Rydén, Gilles Robinet, Edward B. Garon, Tran Van Ngoc

Publikováno v: Journal of Clinical Oncology. 37:9048-9048

9048 Background: MYSTIC, an open-label, Phase 3 trial of first-line D (anti-PD-L1) ± T (anti-CTLA-4) vs platinum CT in mNSCLC, showed an improvement in overall survival (OS) with D vs CT in pts with tumor cell PD-L1 expression ≥25% (TC ≥25% [pri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57b7af66f9f8b760102b6bd9361980c0
https://doi.org/10.1200/jco.2019.37.15_suppl.9048

A randomized phase 2 study of pemetrexed vs. pemetrexed+erlotinib in second-line treatment for locally advanced or metastatic, non-squamous NSCLC

Autor: M. Klima, N. Vinolas, Durisala Desaiah, Christian Dittrich, Monika I. Leschinger, J. von Pawel, Zsolt Papai-Szekely, Christer Sederholm

Publikováno v: Pneumologie. 66

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abf4250f8ca75b9a2f40678c18387332
https://doi.org/10.1055/s-0032-1302878

Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy

Autor: Aleksandra Szczesna, Zsolt Papai-Szekely, Christian H. Ottensmeier, Annette Tavernaro, Enriqueta Felip, Elisabeth Quoix, Frederic Forget, Bérangère Bastien, Jean-Marc Limacher, Gisèle Lacoste, John Nemunaitis, Lucio Crinò

Publikováno v: Journal of Clinical Oncology. 33:3034-3034

3034 Background: TG4010 is an immunotherapy using an attenuated and modified poxvirus (MVA) coding for MUC1 and interleukin-2. A previous study showed that the baseline level of Triple Positive Act...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::fa3d8cc5bb2a94814826ff07dc14315c
https://doi.org/10.1200/jco.2015.33.15_suppl.3034